DS-3032b treatment activated TP53 signaling, as measured by TP53, CDKNA1 and BAX expression, in the xenograft tumor tissue similarly to the neuroblastoma cell lines grown in vitro (Figure 7D). This evidence concerns the gene TP53 and neuroblastoma.